Strategic Acquisition BioCheck’s acquisition of DRG expands its diagnostic reagents and immunoassay capabilities, creating cross-sell opportunities to DRG’s global distributor network and broadening the combined portfolio for both research and diagnostic customers.

Expanded Manufacturing The upgraded manufacturing footprint to support ELISA and CLIA assays positions BioCheck to meet rising global demand for immunoassay solutions, enabling scalable supply for existing partners and new customers in diagnostics and research labs.

Global Reach DRG’s international presence in the US, Germany, Russia, Poland, and the Czech Republic plus extensive distributor partners offer a ready-made channel strategy to accelerate entry into new regional markets and accelerate revenue growth.

Diverse Customer Base Serving diagnostic manufacturers, research laboratories, and healthcare organizations creates multiple entry points for upsell, including higher‑margin immunoassay reagents, assay systems, and turnkey diagnostic solutions.

Growth Potential With revenue in the mid‑range of tens of millions and a near‑two‑to‑three‑decade track record, BioCheck presents an attractive target for channel partnerships, co‑development opportunities, and strategic collaborations to capture market share in mid‑sized to large biomedical players.